04.14.08
SynCo Bio Partners has signed a master services agreement with OncoMed Pharmaceuticals, under which SynCo will fill and finish batches of OncoMed's lead product, antibody OMP-21M18, for use in Phase I clinical trials.
Pierre Warffemius, SynCo's chief executive officer, said, "We are delighted that a company at the forefront of cancer therapies has recognized our expertise in biopharmaceutical processing by choosing us to fill their lead antibody for early clinical trails."
Paul J. Hastings, president and chief executive officer of OncoMed, added, "We selected SynCo Bio Partners because we needed a GMP-accredited contract manufacturing organisation that had a proven track record in filling biologics. With SynCo's expertise in all aspects of biopharmaceutical manufacture, they were an ideal partner for us at this crucial stage in our development."
OncoMed recently announced a worldwide strategic alliance with GlaxoSmithKline to develop cancer stem cell antibody therapeutics. One of the key projects in this alliance will be the development of OMP-21M18, a monoclonal antibody, which is scheduled to enter the clinic in 2008.
SynCo will fill and finish antibody OMP-21M18 at its Amsterdam-based facility. This facility is able to fill a wide range of biopharmaceuticals into vials, including protein, polysaccharide, and live-microbial-based products using the latest filling and finishing equipment, according to a SynCo statement.
Pierre Warffemius, SynCo's chief executive officer, said, "We are delighted that a company at the forefront of cancer therapies has recognized our expertise in biopharmaceutical processing by choosing us to fill their lead antibody for early clinical trails."
Paul J. Hastings, president and chief executive officer of OncoMed, added, "We selected SynCo Bio Partners because we needed a GMP-accredited contract manufacturing organisation that had a proven track record in filling biologics. With SynCo's expertise in all aspects of biopharmaceutical manufacture, they were an ideal partner for us at this crucial stage in our development."
OncoMed recently announced a worldwide strategic alliance with GlaxoSmithKline to develop cancer stem cell antibody therapeutics. One of the key projects in this alliance will be the development of OMP-21M18, a monoclonal antibody, which is scheduled to enter the clinic in 2008.
SynCo will fill and finish antibody OMP-21M18 at its Amsterdam-based facility. This facility is able to fill a wide range of biopharmaceuticals into vials, including protein, polysaccharide, and live-microbial-based products using the latest filling and finishing equipment, according to a SynCo statement.